Bayer AG (FRA:BAYN) has been assigned a €124.00 ($144.19) price objective by analysts at Commerzbank Ag in a research report issued on Wednesday. The firm currently has a “buy” rating on the healthcare company’s stock. Commerzbank Ag’s target price would indicate a potential upside of 15.03% from the company’s previous close.

Several other research analysts have also recently weighed in on the company. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Bayer AG in a research note on Wednesday, September 13th. The Goldman Sachs Group, Inc. set a €125.00 ($145.35) target price on Bayer AG and gave the company a “buy” rating in a report on Monday, July 24th. Sanford C. Bernstein set a €126.00 ($146.51) price objective on Bayer AG and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Nord/LB set a €106.00 ($123.26) price objective on Bayer AG and gave the stock a “neutral” rating in a research note on Friday, July 28th. Finally, Baader Bank set a €140.00 ($162.79) price target on Bayer AG and gave the stock a “buy” rating in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of €122.43 ($142.36).

Bayer AG (FRA:BAYN) traded down €0.10 ($0.12) during trading hours on Wednesday, hitting €107.80 ($125.35). The stock had a trading volume of 1,009,990 shares. Bayer AG has a 12 month low of €86.06 ($100.07) and a 12 month high of €123.82 ($143.98).

ILLEGAL ACTIVITY WARNING: “Bayer AG (BAYN) Given a €124.00 Price Target by Commerzbank Ag Analysts” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at

Bayer AG Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer AG (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with Analyst Ratings Network's FREE daily email newsletter.